WO2024257023 - TYK2 PSEUDOKINASE LIGANDS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2024/257023
Publication Date
19.12.2024
International Application No.
PCT/IB2024/055815
International Filing Date
14.06.2024
Title **
[English]
TYK2 PSEUDOKINASE LIGANDS AND USES THEREOF
[French]
LIGANDS DE PSEUDOKINASE TYK2 ET LEURS UTILISATIONS
Applicants **
ALEMBIC PHARMACEUTICALS LIMITED
Alembic City, Alembic Road, Vadodara
Gujarat 390003, IN
Inventors
KURHADE, Suresh
c/o Alembic Pharmaceuticals Limited
2nd Floor, Building 2700, MN Takshila Park
Genome Valley, Hyderabad
Telangana 500078, IN
PRIYADARSHANI, Garima
c/o Alembic Pharmaceuticals Limited
2nd Floor, Building 2700, MN Takshila Park
Genome Valley, Hyderabad
Telangana 500078, IN
SISODIYA, Shailendra
c/o Alembic Pharmaceuticals Limited
2nd Floor, Building 2700, MN Takshila Park
Genome Valley, Hyderabad
Telangana 500078, IN
HALLE, Mahesh
c/o Alembic Pharmaceuticals Limited
2nd Floor, Building 2700, MN Takshila Park
Genome Valley, Hyderabad
Telangana 500078, IN
KAPURE, Jeevak Sopanrao
c/o Alembic Pharmaceuticals Limited
2nd Floor, Building 2700, MN Takshila Park
Genome Valley, Hyderabad
Telangana 500078, IN
KURIAPPAN, Jissy Akkarapattiakal
c/o Alembic Pharmaceuticals Limited
2nd Floor, Building 2700, MN Takshila Park
Genome Valley, Hyderabad
Telangana 500078, IN
MALLIK, Sanchari Basu
c/o Alembic Pharmaceuticals Limited
2nd Floor, Building 2700, MN Takshila Park
Genome Valley, Hyderabad
Telangana 500078, IN
TANDON, Amol
c/o Alembic Pharmaceuticals Limited
2nd Floor, Building 2700, MN Takshila Park
Genome Valley, Hyderabad
Telangana 500078, IN
SUBRAMANIAM, Ganesan
c/o Alembic Research Centre, Alembic Pharmaceuticals Limited, Alembic Road, Vadodara
Gujarat 390003, IN
IYER, Abishek Venkatasubramanian
c/o Alembic Pharmaceuticals Limited
2nd Floor, Building 2700, MN Takshila Park
Genome Valley, Hyderabad
Telangana 500078, IN
Priority Data
202321040658
14.06.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 4960 | |
| EPO | Filing, Examination | 68204 | |
| Japan | Filing | 590 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 24010 |
Total: 98339 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Described herein are compounds of formula (A) that are useful in the modulation of inflammation and treating associated disorders by acting on TYK2 to cause TYK2-mediated signal transduction inhibition. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, an endocrine disorder, a neurological disorder, a proliferative disorder, or a disorder associated with transplantation.[French]
L'invention concerne des composés de formule A qui sont utiles dans la modulation de l'inflammation et le traitement de troubles associés par action sur TYK2 pour provoquer une inhibition de la transduction de signal médiée par TYK2. Dans certains modes de réalisation, le trouble médié par TYK2 est un trouble auto-immun, un trouble inflammatoire, un trouble endocrinien, un trouble neurologique, un trouble prolifératif ou un trouble associé à une transplantation.